Sizofiran (Schizophyllan)

09/01/1986 - "[Combination therapy of radiation and schizophyllan (SPG) in C3H mouse squamous-cell carcinoma NR-S1]."
01/01/1992 - "The efficacy of Sizofiran(SPG), a highly purified beta-1,3-D-glucan from the culture broth of basidiomycetes Schizophyllum commune Fries, in combination with local irradiation was investigated using squamous-cell carcinoma NR-S1 and syngeneic hosts of C3H/He mice. "
09/01/1986 - "The efficacy of schizophyllan, a beta-1, 3-D-glucan with a beta-1, 6-linked D-glucose residue isolated from Schizophyllum commune Fries, in combination with local radiation therapy was investigated using C3H mouse squamous-cell carcinoma NR-S1. "
01/01/1992 - "Combination therapy of radiation and Sizofiran (SPG) on the tumor growth and metastasis on squamous-cell carcinoma NR-S1 in syngeneic C3H/He mice."
08/29/1994 - "Treatment of squamous cell carcinoma (SCCVII) bearing mice with the immunostimulant schizophyllan (SPG) raised the relative content of Mac-1 positive host cells infiltrating the tumor and increased photofrin retention in these tumors. "

01/01/1997 - "Augmentation of protective immune responses against viral infection by oral administration of schizophyllan."
01/01/1993 - "The present results suggest that schizophyllan confers better protection against virus infection through augmentation of antiviral immune responses and can be used as an immune enhancer."
01/01/1997 - " results suggest that schizophyllan confers effective protection against viral infection by increasing antiviral immune responses, and that it could be used to boost immunity to virus infection in animals or in invertebrates."
01/01/1993 - "Antiviral antibody in the serum could be detected at an earlier time after virus infection and virus spread in the lung was more efficiently inhibited in schizophyllan-treated mice than in untreated controls. "

11/01/1994 - "As it is important to determine the optimal serum concentration of schizophyllan (SPG) when it is used as an anti-cancer drug, we devised a solid-phase ELISA. "
05/01/1993 - "The immunological stimulation with Sizofiran in 20 patients led to an augmentation of ILC in tumor tissues. "
01/01/1993 - "Sizofiran seems to assure a sufficient supply of M phi to kill tumor cells in the peritoneal cavity and co-administered rIFN-gamma seems to directly stimulate the accumulated M phi in addition to its direct cytotoxicity against tumor cells. "
01/01/1991 - "Although the overall survival probability for 5 years did not differ between the SPG and control groups, in 264 patients with curatively resected cancer, the probability to 5 year survival and to recurrence in the sizofiran-administered patients was better than in the controls. "
10/20/1990 - "It has been well known that Sizofiran (SPG) cultured from the Schizophyllum commune Fries activates the macrophages and induces the cytotoxic lymphocytes in some cancers. "

02/01/1992 - "Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. "
10/05/2010 - "Therefore, in patients with cervical cancer, it is important to confirm whether or not sizofiran has been administered before measuring (1→3)-beta-d-glucan levels."
10/05/2010 - "The plasma level of (1→3)-beta-d-glucan was very high, and this elevated level was attributed to administration of sizofiran for treatment of cervical cancer 18 years previously. "
08/01/2007 - "Schizophyllan (SPG) is used to treat cervical cancer in combination with irradiation to enhance the immunological surveillance system. "
04/01/1996 - "Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer."

01/01/1998 - "Augmentation of the antitumor effect of adoptive immunotherapy by in vivo sensitization of EL-4 lymphoma and pre-treatment with sizofiran."
01/01/1996 - "We have reported that combined administration with recombinant interleukin-2 (rIL-2) and sizofiran (SPG) is effective in prolonging survival time of C57BL/6 mice intraperitoneally inoculated with EL-4 lymphoma. "
01/01/1998 - "The antitumor effects of adoptive immunotherapy using LAK cells treated with sizofiran (SPG) following in vivo antigen sensitization with EL-4 lymphoma (EsLAK), comparing nonsensitized LAK cells (sLAK), were studied in mice with intraperitoneal implantation of EL-4 lymphoma. "
07/01/1994 - "[Immunotherapy of malignant lymphoma with interleukin-2 and sizofiran--a basic study on EL-4 lymphoma-transplanted mice]."
07/01/1994 - "The anti-tumor effects of recombinant human interleukin-2 (rIL-2) and sizofiran (SPG) were evaluated individually and in combination in C57BL/6 mice intraperitoneally inoculated with EL-4 lymphoma. "